AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review
{{output}}
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are linked to immune-related adverse events (irAEs). Secondary (AA) amyloidosis, an inflammatory complication involving serum amyloid A depositio... ...
